Navigation Links
Low micro-RNA level linked to high gene activity in AML
Date:3/6/2008

COLUMBUS, Ohio A new study suggests that a type of acute leukemia may occur in part because abnormally low levels of one small molecule result in the over-activity of genes important to the disease.

The research involved patients with acute myeloid leukemia (AML) and a gene mutation called NPM1, an alteration seen in about one-third of adult AML cases.

The findings suggest new therapeutic targets for treating the disease and should improve the understanding of AML, researchers say.

The study showed that a type of microRNA molecules important in controlling cell development and proliferation regulates two genes whose elevated activity has been linked to leukemia in humans and proven to cause leukemia in mice.

The two genes belong to the Hox family of genes, known to play a critical role in embryonic development and blood-cell development.

The study, led by researchers at the Ohio State University Comprehensive Cancer Center, was published online Feb. 28 in the Proceedings of the National Academy of Sciences.

Weve shown that low levels of a microRNA called miR-204 are at least partly responsible for the high activity of these Hox genes, says first author Dr. Ramiro Garzon, an Ohio State cancer researcher.

If this is verified, and if we can develop a drug to modulate this microRNA, it may provide a new therapeutic intervention for these patients.

For this study, the investigators examined microRNAs levels in leukemia cells from 85 patients. They also looked for mutations in two genes in the leukemic cells: NPM1 and FLT3 (pronounced Flit-3).

The pattern of microRNA molecules present in the cells enabled the researchers to distinguish the 55 patients with mutated NPM1 genes from those with a normal gene.

Furthermore, 26 of the 85 patients had FLT3 mutations. These cases also had high levels of a microRNA called miR-155. Further experiments showed that while the high levels of miR-155 were closely associated with FLT3 mutations, they were independent of the mutation (i.e., it did not cause the high levels).

This is significant, says Garzon, an assistant professor of internal medicine. We already have drugs that target FLT3, but they are not effective by themselves. This finding suggests that if we develop a drug that targets miR-155, and combine it with a FLT3 inhibitor, we might achieve a more complete response in these patients.

Garzon and his colleagues are studying that possibility now.


'/>"/>

Contact: Darrell E. Ward
darrell.ward@osumc.edu
614-293-4833
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Estrogen Levels in Blood Predict Breast Cancers Return
2. Mother-daughter conflict, low serotonin level may be deadly combination
3. Atypical protein kinase C stabilizes SRC-3 levels in breast cancer cells
4. Next Step(R) Institute of Integrative Medicine, Inc. Takes Wellness to a New Level With 2008 Series of Wellness Weeks
5. Moderate Aerobic Fitness Levels May Cut Stroke Risk
6. Novel link between excessive nutrient levels and insulin resistance
7. Cleveland Clinic Collaborates with Google
8. ADAMS Performs Management Services for University Hospitals $600 Million Expansion/Renovation Program in Cleveland, OH
9. Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy
10. Climb to Fight Breast Cancer Offers Peaks for Every Skill Level
11. Oscar Pistorius Aims to Compete on Level Playing Field at 2008 Beijing Olympics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... ComplianceOnline, the leading governance, risk and compliance ... summit on September 15 and 16, 2016 in San Diego, CA. The two ... bearers will be one of the largest gatherings of medical device companies, suppliers, professionals ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... today that nominations will be accepted May 23, 2016 through August 5, ... include the Information Security Executive® of the Year, which recognizes executives who ...
(Date:5/23/2016)... ... May 23, 2016 , ... Hadley ... worldwide for people who are blind or visually impaired, announces the election of ... President Charles E. Young. Hadley’s Board of Trustees retained Morris & Berger, a ...
(Date:5/23/2016)... ... 23, 2016 , ... Octo Consulting Group, a leading provider of innovative information ... announce they have recently won two awards from AFCEA International. Octo was selected ... Year. Additionally, Octo VP of Civilian Affairs, Naina Leo, was named a winner of ...
(Date:5/23/2016)... , ... May 23, 2016 , ... VitreosHealth is presenting ... 10, 2016 from 11:00 AM – 12:00 PM ET. To register, click ... start a proactive outreach program built on Big Data with a new predictive and ...
Breaking Medicine News(10 mins):
(Date:5/20/2016)... 2016 ReportsnReports.com adds Global ... Devices of its online business intelligence library. This ... current state of the Titrator industry. The report ... definitions, classifications, Specifications, applications and industry chain structure. ... Raw Material Suppliers, Equipment Suppliers, Manufacturing Cost Structure, ...
(Date:5/20/2016)... India , May 20, 2016 ... - Pipeline Review, H1 2016" market research report ... Plaque Psoriasis (Psoriasis Vulgaris), complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology: